Literature DB >> 27659716

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.

Silvan Francke1, Anna Mies1, Manja Meggendorfer2, Uta Oelschlaegel1, Ekaterina Balaian1, Silke Gloaguen1, Torsten Haferlach2, Gerhard Ehninger1, Martin Bornhäuser1, Uwe Platzbecker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27659716     DOI： 10.1080/10428194.2016.1225209

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.

Authors:  Jennifer Chapman; Julia T Geyer; Mahsa Khanlari; Adrienne Moul; Carmen Casas; Scot T Connor; Yao-Shan Fan; Justin M Watts; Ronan T Swords; Francisco Vega; Attilio Orazi
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842

2.  The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

Authors:  Tamara K Moyo; Jason H Mendler; Raphael Itzykson; Ashwin Kishtagari; Eric Solary; Adam C Seegmiller; Aaron T Gerds; Gregory D Ayers; Amy E Dezern; Aziz Nazha; Peter Valent; Arjan A van de Loosdrecht; Francesco Onida; Lisa Pleyer; Blanca Xicoy Cirici; Raoul Tibes; Klaus Geissler; Rami S Komrokji; Jing Zhang; Ulrich Germing; David P Steensma; Daniel H Wiseman; Michael Pfeilstöecker; Chiara Elena; Nicholas C P Cross; Jean-Jacques Kiladjian; Michael Luebbert; Ruben A Mesa; Guillermo Montalban-Bravo; Guillermo F Sanz; Uwe Platzbecker; Mrinal M Patnaik; Eric Padron; Valeria Santini; Pierre Fenaux; Michael R Savona
Journal:  BMC Cancer       Date:  2022-09-24       Impact factor: 4.638
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.